At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 832 enrolled
Drug / intervention
tanezumab 10 mg +3 morebiological
Likely dose
tanezumab 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3 RANDOMIZED, DOUBLE BLIND PLACEBO AND NAPROXEN CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
In Brief
A Phase 3 clinical trial evaluating tanezumab 10 mg, tanezumab 5 mg, and 2 other interventions for Arthritis and Osteoarthritis. Completed, enrolled 832 participants across 94 sites.
Detailed Summary
The purpose of this study is to test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Osteoarthritis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartMay 2009
Primary CompletionMay 2010
Study CompletionAug 2010
TodayJul 2026
First PostedJan 27, 2009
Enrollment StartMay 5, 2009
Primary CompletionMay 17, 2010
Study CompletionAug 31, 2010
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 17.4 years ago
Interventions
tanezumab 10 mgbiological
tanezumab 10 mg one dose at weeks 0 and 8
tanezumab 5 mgbiological
tanezumab 5 mg one dose at weeks 0 and 8
naproxendrug
naproxen 1000 mg daily for 16 weeks
placeboother
placebo to match tanezumab and naproxen dosing